Keryx Biopharmaceuticals Announces Ferric Citrate

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Keryx Biopharmaceuticals Announces Ferric Citrate Presentations at the Upcoming American Society of Nephrology Kidney Week 2014 Annual Meeting

Pharmacoeconomic Abstract Selected for Oral Presentation

Results from a Long-Term Safety Extension Study in Chronic Kidney Disease 
Selected as a Late-Breaking Poster Presentation

NEW YORK, Oct. 23, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced  that two Ferric Citrate-related abstracts have been accepted for presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2014 annual meeting in Philadelphia, PA from November 11-16, 2014. An abstract regarding the pharmacoeconomic impact of Ferric Citrate has been selected for oral presentation and an abstract with results from the long-term open label extension ("OLE") study of Ferric Citrate in dialysis dependent chronic kidney disease ("CKD") patients with elevated serum phosphorus has been selected as a late-breaking poster presentation. These abstracts are now available on the ASN website.

Details of the presentations are as follows:

Friday, November 14 th

  • Abstract # FR-OR045
    • Description: The potential pharmacoeconomic impact of Ferric Citrate.
    • Session Name: Dialysis Identifying Risk Factors and Improving Noncardiovascular Outcomes
    • Presentation Time: 4:30PM

Saturday, November 15 th :

  • Abstract # SA-PO1102
    • Description: Results from the long-term open label extension ("OLE") study of Ferric Citrate in dialysis dependent chronic kidney disease ("CKD") patients with elevated serum phosphorus.
    • Session Name: Late-Breaking Posters
    • Presentation Time: 10:00 a.m. – 12:00 noon

"We are thrilled about the presentations of key clinical and pharmacoeconomic data that we believe can further reinforce Ferric Citrate's value, at the upcoming ASN conference, occurring just a few weeks before our expected launch," stated Ron Bentsur, Chief Executive Officer of Keryx. "This conference is an outstanding renal venue known for its high academic standards and typically draws over 10,000 treating nephrologists and dialysis professionals from the U.S. and abroad."

About Ferric Citrate

Ferric Citrate was approved by the U.S. Food and Drug Administration on September 5, 2014 and is indicated in the U.S. for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Keryx plans to make Ferric Citrate available to U.S. dialysis patients in early December.

In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. 

Keryx has filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA), seeking the approval of Ferric Citrate as a treatment of hyperphosphatemia in patients with CKD, including dialysis and non-dialysis dependent patients, and that application is currently under review.

Ferric Citrate is also being developed in the U.S. as a treatment for iron deficiency anemia in patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease (CKD). The pivotal Phase 3 study in this indication commenced in September 2014.

For Full Prescribing Information for Ferric Citrate, please visit http://www.keryx.com/wp-content/uploads/Keryx...ate_PI.pdf .

Important Safety Information about Ferric Citrate

Contraindication:  Patients with an accumulation of iron in their body, e.g. hemochromatosis, should not take Ferric Citrate.

Iron Overload:  Iron absorption from Ferric Citrate may lead to increased iron in storage sites. Iron parameters should be monitored prior to and while on Ferric Citrate. Patients receiving IV iron may require a reduction in dose or discontinuation of IV iron therapy.

Accidental Overdose of Iron:  Keep Ferric Citrate away from children as it contains iron. Accidental overdose of iron containing products is a leading cause of fatal poisoning in children under 6 years of age . Call a poison control center or your physician in case of an accidental overdose in a child.

Patients with Gastrointestinal Bleeding or Inflammation:  Safety has not been established for these patients.

Adverse Events: The most common adverse events with Ferric Citrate were diarrhea (21%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%) .  Gastrointestinal adverse reactions were the most common reason for discontinuing Ferric Citrate (14%).

Ferric Citrate contains iron and may cause dark stools, which is considered normal with oral medications containing iron.

Drug Interactions:  Doxycycline should be taken at least 1 hour before Ferric Citrate. 

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, headquartered in New York, is focused on bringing innovative therapies to market for patients with renal disease. The Company's lead product, Ferric Citrate, is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. Keryx plans to commercially launch Ferric Citrate in the U.S. in the fourth quarter of 2014. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona ® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd.  For more information about Keryx, please visit www.keryx.com .

Cautionary Statement

Some of the statements included in this press release, particularly those regarding the commercialization of Ferric Citrate, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: whether Ferric Citrate will be successfully launched and marketed in the U.S.; whether the FDA will approve a brand name for Ferric Citrate prior to the projected launch date; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com . The information found on our website and the ASN website is not incorporated by reference into this press release and is included for reference purposes only.

Amy Sullivan Vice President - Corporate Development and Public Affairs Keryx Biopharmaceuticals, Inc. Tel: 617.466.3447 E-mail:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 29

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 213

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 99

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 85

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 141

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
BioArctic's Q3 Call Puts Leqembi Economics Under Watch

Updated Category News Views 32

One Date, Several Unanswered Questions November 25 lands with an unusually clean checklist for BioArctic watchers: results arrive at 8:00 a.m. CET, then management takes the floor at 9:30 a.m. CET. That is the whole immediate event, and it matters because this is not a company investors can sensibly judge by a single headline or a vague promise about neuroscience....

Continue Reading
LONGi's Solar-Storage Push Faces Africa's Cost Wall

Updated Category News Views 22

A vaccine refrigerator humming through a blackout is more meaningful than another climate-conference slogan. That was the useful thread running through LONGi's November 13 COP31 side event in Antalya, Türkiye: solar and storage are not merely hardware for remote communities. When designed, financed and maintained properly, they can keep clinics, water pumps and other...

Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific

Updated Category News Views 149

Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....

Continue Reading
Midea's Cooling Systems Take Center Stage at DCW ME

Updated Category News Views 121

AI Surge Demands Cooler Solutions Alright, who'd guess that data centers would feel the heat—literally—like a welder's furnace in Abu Dhabi? As AI demand burns hotter across the Middle East, data centers are sweating it out against 50°C-plus temperatures. We're talking about some serious pressure on traditional cooling methods that just can’t cut it anymore....

Continue Reading

Top 5 Most Recently Viewed Articles

Securities Fraud Investigation Casts Shadow on Driven Brands

Updated Category News Views 331

The Unfolding Drama Surrounding Driven Brands Out of nowhere, the waters are getting choppy for Driven Brands Holdings, and it’s not just a casual dip; more like a tsunami warning. Ademi LLP is cranking up the heat with an investigation into possible securities fraud that’s got investors scratching their heads and probably running for cover. What’s the Big Deal?...

Continue Reading
Info-Tech Research Group Expands Focus in Asia-Pacific Markets

Updated Category News Views 292

Info-Tech Research Group Expands Its Global Footprint Info-Tech Research Group has recently expanded its global presence by launching a new office in Singapore while significantly ramping up investments in New Zealand. This strategic move enables the firm to provide more localized, outcome-driven support to IT leaders throughout Southeast Asia and the Australia-New...

Continue Reading
Laramide Resources' Strategic Exploration Plans in Kazakhstan

Updated Category News Views 144

Exploration Drilling Plans by Laramide Resources Laramide Resources Ltd., a leading organization in uranium exploration, has identified multiple promising targets within its Chu-Sarysu Project. This initiative is set to take place in a mineral-rich area renowned for its potential to yield significant deposits of uranium and other valuable minerals like rare earth elements...

Continue Reading
Stravito Unveils AI Personas for Accelerated Market Insights

Updated Category News Views 311

Stravito Introduces AI Personas for Enhanced Market Positioning Stravito supports brands in rapidly validating their ideas using advanced AI technology. In a dynamic market environment, Stravito has launched an initiative designed to drastically improve the speed and reliability of idea testing for brands. This revolutionary tool, known as Stravito AI Personas, transforms...

Continue Reading
Duni Introduces Innovative Take-Away Series Boosting Sustainability

Updated Category News Views 245

Duni Introduces Innovative Take-Away Series Boosting Sustainability Duni is excited to unveil a fresh series of take-away packaging that represents a significant leap towards sustainability. The company has developed new packaging solutions that feature a grey plastic base, which can significantly enhance recycling efforts compared to traditional black plastic. This move...

Continue Reading